216,228 Shares in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Bought by XTX Topco Ltd

Key Points

• XTX Topco Ltd purchased 216,228 shares of Xeris Biopharma Holdings, Inc. valued at approximately $1.187 million, representing a 0.14% ownership stake in the company.
• Xeris Biopharma's most recent financial report showed a narrower-than-expected loss of ($0.06) EPS, and revenue of $57.80 million, surpassing analyst predictions.
• Wall Street analysts have mixed ratings on Xeris Biopharma, with a consensus "Moderate Buy" rating and an average target price of $6.25 for the stock.

XTX Topco Ltd bought a new position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) during the first quarter, according to its most recent disclosure with the SEC. The firm bought 216,228 shares of the company's stock, valued at approximately $1,187,000. XTX Topco Ltd owned 0.14% of Xeris Biopharma as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Xeris Biopharma by 4.5% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 80,388 shares of the company's stock valued at $273,000 after acquiring an additional 3,447 shares during the period. Wealth Enhancement Advisory Services LLC raised its holdings in Xeris Biopharma by 31.0% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 16,268 shares of the company's stock valued at $55,000 after acquiring an additional 3,847 shares during the period. Apollon Wealth Management LLC raised its holdings in Xeris Biopharma by 19.8% during the first quarter. Apollon Wealth Management LLC now owns 24,160 shares of the company's stock valued at $133,000 after acquiring an additional 4,000 shares during the period. Prudential Financial Inc. raised its holdings in Xeris Biopharma by 23.4% during the fourth quarter. Prudential Financial Inc. now owns 36,945 shares of the company's stock valued at $125,000 after acquiring an additional 7,000 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its holdings in Xeris Biopharma by 5.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 170,482 shares of the company's stock valued at $578,000 after acquiring an additional 9,506 shares during the period. 42.75% of the stock is owned by institutional investors.

Xeris Biopharma Trading Up 5.7%

XERS opened at $5.38 on Friday. The firm has a market cap of $841.32 million, a P/E ratio of -17.93 and a beta of 0.65. Xeris Biopharma Holdings, Inc. has a 12 month low of $2.10 and a 12 month high of $6.07. The stock has a 50-day moving average of $4.84 and a 200 day moving average of $4.48.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.01. The company had revenue of $57.80 million during the quarter, compared to analysts' expectations of $57.61 million. On average, research analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on XERS shares. Wall Street Zen cut Xeris Biopharma from a "buy" rating to a "hold" rating in a report on Thursday, May 22nd. Oppenheimer raised their price target on Xeris Biopharma from $6.00 to $7.00 and gave the company an "outperform" rating in a report on Friday, May 9th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $6.25.

Insider Buying and Selling

In other news, insider Kevin Mcculloch acquired 25,000 shares of the firm's stock in a transaction on Friday, June 13th. The stock was acquired at an average price of $4.38 per share, with a total value of $109,500.00. Following the completion of the purchase, the insider directly owned 1,708,585 shares in the company, valued at approximately $7,483,602.30. This trade represents a 1.48% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 6.47% of the company's stock.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.